SPHRF - Starpharma's SPL7013 Antiviral Takes On COVID-19

Starpharma VivaGel antiviral condom launched in Japan under Okamoto 003 brand

Last month I wrote an article suggesting that Starpharma’s (OTCQX:OTCQX:SPHRY) share price has been savaged by COVID-19 for no good reason. Now Starpharma is showing signs of fighting back against the coronavirus SARS-CoV-2 which causes COVID-19. Here I summarise my thoughts about the prospects for Starpharma’s SPL7013 antiviral having a role in the COVID-19 story. The possible COVID-19 treatment adds some sizzle to an already interesting opportunity.

It is tough for a non-technical investor to make sense of prospective treatments and vaccines